According to recent advances in chemotherapy containing adriamycin, now complete remission can be obtained in more than 80 percent of patients with stage 3 and 4 diffuse large cell lymphomas, and the cure rate could also be expected in more than 60 percent of patients. The easiest way to obtain better results would be the introduction of chemotherapy in stage 1 and 2. The kinds of chemotherapy chosen in planning the design of the treatment should be such as to eradicate microdisseminated disease, and only such chemotherapy will contribute to improvement in survival rates.